Lifecore Biomedical, Inc. - Common Stock (LFCR)

U.S. stock futures were higher on Friday, the slipping in first trading session of 2025. All four index futures advanced in premarket trade.

US stock futures up, GeneDx appoints new COO, Lifecore beats expectations, SPS Commerce acquires Carbon6, Resources Connection & UDR report strong quarters.

The CNN Money Fear & Greed index showed a slight easing in fear, while US stocks closed lower but still recorded gains in 2024.

LFCR stock results show that Lifecore Biomedical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

U.S. stocks traded higher toward the end of trading, after the Federal Reserve left rates unchanged. The Dow traded up 0.91% to 39,467.76 while the NASDAQ rose 1.08% to 16,341.42. The S&P 500 also rose, gaining, 0.78% to 5,218.70.

Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it concluded its strategic evaluation process, announced management succession and board changes. Lifecore Biomedical shares dipped 31.7% to $4.91 on Wednesday.

U.S. stocks traded mostly flat midway through trading, ahead of interest-rate decision from the Federal Reserve. The Dow traded up 0.03% to 39,123.89 while the NASDAQ fell 0.01% to 16,165.15. The S&P 500 also rose, gaining, 0.01% to 5,178.79.

U.S. stocks traded slightly lower this morning, ahead of interest-rate decision from the Federal Reserve. Following the market opening Wednesday, the Dow traded down 0.01% to 39,106.88 while the NASDAQ fell 0.06% to 16,157.27. The S&P 500 also fell, dropping, 0.02% to 5,177.26.

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

The most overbought stocks in the consumer staples sector presents an opportunity to go short on these overvalued companies.

Lifecore Biomedical Inc (NASDAQ: LFCR) reported a Q3 FY23 revenue decline of 26% Y/Y to $27.60 million,

Companies Reporting Before The Bell • Hormel Foods (NYSE:HRL) is likely to report quarterly earnings at $0.40 per share on revenue of $3.05 billion.

Gainers